# Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis

> clinical trial · VERIFIED · 2026-07-13

Status: RECRUITING · Sponsor: Mannkind Corporation · Condition: Idiopathic Pulmonary Fibrosis

- Company: Mannkind Corporation
- Sector: Idiopathic Pulmonary Fibrosis
- Primary source: https://clinicaltrials.gov/study/NCT07679893

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.